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Background: In compliance with national and international guidelines, non-pregnant women with cervical
intraepithelial neoplasia grade 3 should be treated by cervical conization. According to the definition of the large loop
excision of the transformation zone (LLETZ) operation, the lesion needs to be resected, including the transformation
zone. It is well known from the literature that the cone size directly correlates with the risk of preterm delivery in the
course of a future pregnancy. Thus, it would be highly desirable to keep the cone dimension as small as possible while
maintaining the same level of oncological safety.
Methods/Design: The aim of this study is to analyze whether resection of the lesion only, without additional excision
of the transformation zone, is equally as effective as the classical LLETZ operation regarding oncological outcome. We
are performing this prospective, patient-blinded multicenter trial by randomly assigning women who need to undergo
a LLETZ operation for cervical intraepithelial neoplasia grade 3 to either of the following two groups at a ratio of 1:1: (1)
additional resection of the transformation zone or (2) resection of the lesion only. To evaluate equal oncological
outcome, we are performing human papillomavirus (HPV) tests 6 and 12 months postoperatively. The study is designed
to consider the lesion-only operation as oncologically not inferior if the rate of HPV high-risk test results is not
higher than 5 % compared with the HPV high-risk rate of women undergoing the classical LLETZ operation.
Discussion: In case that non-inferiority of the “lesion-only” method can be demonstrated, this operation should
eventually become standard treatment for all women at childbearing age due to the reduction in risk of preterm delivery.
Trial registration: German Clinical Trials Register (DRKS) Identifier: DRKS00006169. Date of registration: 30 July 2014.
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Cervical cancer is the third most common cancer diag-
nosis and the fourth-leading cause of death in women
worldwide, responsible for 9 % (529,800) of all new can-
cer cases and 8 % (275,100) of deaths caused by cancer
in women in 2008 [1].
Precursor lesions of squamous cell carcinoma of the cer-
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unless otherwise stated.are referred to as cervical intraepithelial neoplasia (CIN),
which is distinguished in three degrees of severity (CIN 1
to 3) [2]. Compared with invasive cervical cancer, the oc-
currence of precancerous lesions of the cervix uteri is
much higher.
A prerequisite for the development of cervical dysplasia
is a persistent infection with high-risk human papillomavi-
rus (HPV) types [3]. Anogenital HPV infection is a com-
mon sexually transmitted disease, estimated to affect 75 %
to 80 % of sexually active adults younger than age 50 years
[4]. The majority of HPV infections are self-limitingl. This is an Open Access article distributed under the terms of the Creative
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ticularly HPV 16 and 18, are responsible for the vast ma-
jority of cervical cancers [6], whereas low-risk HPV types
are associated with condylomata acuminata.
HPV infections affect undifferentiated basal cells of
the cervical epithelium within the transformation zone.
The transformation zone is the area of the cervix where
the columnar epithelium of the endocervix meets the
squamous epithelium of the ectocervix.
Before puberty, the squamocolumnar junction lies
within the endocervical canal. Owing to hormonal
changes during puberty, the columnar epithelium extends
outward and the squamocolumnar junction moves onto
the ectocervix. Under exposure to the acidic vaginal envir-
onment, columnar epithelium can undergo physiological
metaplasia and transform into squamous epithelium. The
new squamocolumnar junction is then closer to the endo-
cervix compared with the original squamocolumnar junc-
tion, and the zone in between is called the transformation
zone of the cervix. Recently, a hypothesis has been stated
that cervical cancer emerges from a newly described em-
bryological cell population. These so-called cuboid cells
are located directly at the squamocolumnar junction [7].
In accordance with national and international guide-
lines [8], standard treatment of non-pregnant women di-
agnosed with CIN 3 is conization of the cervix. This
procedure is also called large loop excision of the trans-
formation zone (LLETZ). The rationale for the removal
of the transformation zone in addition to the lesion itself
is that both the precursor lesion and cervical cancer it-
self typically arise in the area of the transformation zone.
In addition to general complications such as intraopera-
tive or postoperative bleeding, infection, pain and scarring,
cervical conization is associated with a significantly high
rate of cervical weakness and a consequent increase in mis-
carriages and premature birth rates in future pregnancies
[9–12]. This is of special interest because patients diag-
nosed with cervical dysplasia are typically of childbearing
age, with an average age of 30 years [13, 14]. It is well
known that the risk of preterm birth is directly correlated
with the size of the removed cone [15–17]. With know-
ledge of these serious complications, there is a worldwide
trend aimed at reducing surgical radicalism by removing
the dysplastic lesion only, without additional resection of
the transformation zone.
In a large retrospective study of over 150,000 women
treated for CIN 3 between 1958 and 2008, it has lately
been shown that women who received treatment more
recently were at greater risk of developing cervical can-
cer [18]. It is suggested that this observation directly
correlates with the use of less aggressive treatment over
the last two decades [19].
With awareness of this development, it is important to
respecify the necessary extent of a conization. Primarily,the optimum cone size needs to guarantee the highest
oncological safety defined by low recurrence and high
R0 resection rates. Simultaneously, the extent of the re-
section should be as small as possible to reduce the mor-
bidity risk during subsequent pregnancies.
The primary objective of the present study is therefore
to compare the classical LLETZ operation (that is, resec-
tion of the lesion with entrainment of the transformation
zone) with resection of the colposcopically abnormal le-
sion only in the light of oncological safety.
Methods/Design
Study design
The Evaluation of Clinical Outcome after Reduction of
Conization Size (or ECO-ROCS) trial is a multicenter, pro-
spective, parallel-group, patient-blinded, non-inferiority
randomized controlled trial in which we are assessing
oncological comparability of two conization procedures:
(1) classical LLETZ, comprising excision of the dysplastic
lesion, including resection of the transformation zone; and
(2) excision of the dysplastic lesion only.
Study setting
This study is being conducted in 13 study centers, all of
which run a specialized dysplasia clinic (Munich (two),
Hannover, Wolfsburg, Berlin, Kiel, Regensburg, Stralsund,
Hamburg, Düsseldorf, Aachen, Ulm, Münster). The par-
ticipating study centers and investigators are fully listed in
the German Clinical Trials Register (DRKS00006169).
Sample size and statistics
A sample size of 892 patients was calculated with the
POWER procedure of SAS for Linux 9.3 software (SAS
Institute, Cary, NC, USA) using the following parame-
ters: non-inferiority margin of 5 %, α = 0.05, 80 % power
and one-sided test. A rate of 90 % negative HPV test re-
sults 6 months after conization was taken as a reference
[20] for both groups. Assuming a 10 % dropout rate, we
aim for a sample size of 1000 patients.
The statistical inference regarding the primary out-
come will be based on a one-sided 95 % confidence
interval for the risk difference, calculated as the propor-
tion of HPV-positive patients in the control group minus
the corresponding proportion in the experimental group.
If the upper limit of the confidence interval is less than
the non-inferiority margin of minus 5 %, non-inferiority
will be regarded as established.
Recruitment und randomization
Patients are being seen and diagnosed in specialized dys-
plasia outpatient clinics of the participating study centers.
After they provide us their written informed consent, par-
ticipants fulfilling all required inclusion and exclusion cri-
teria are given a five-digit pseudonym (patient identifier),
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the latter three numbers indicating a sequential patient
number. Patients are randomly assigned by their pseudo-
nym with equal probability to either of the two treatment
arms, using a 1:1 ratio. Randomization is carried out using
the web-based Randoulette randomization service of the In-
stitute for Medical Informatics, Biometry and Epidemiology,
University of Munich, Germany. The platform offers a
web-based form in which to enter patient identifier, sex,
age and study center, as well as the strata of the patient.
Access to the randomization service is provided to the
two leading investigators at each study center. Patients are
stratified by age (>30 or ≤30 years) and study center.
After the information is entered, the study arm is se-
lected according to a predefined randomization scheme, in
this case an unblended, stratified block randomization. To
maintain allocation concealment, the exact length of blocks
is kept secret by the Randoulette randomization service.
The entered information, as well as the randomization re-
sults, are stored in the Randoulette database.Fig. 1 Resection margins of classical large loop excision of the
transformation zone operation including the transformation zone,
which is defined as 3 to 4 mm around the squamocolumnar
junction. CIN, Cervical intraepithelial neoplasia; LLETZ, Large loop
excision of the transformation zone; SCJ, Squamocolumnar junctionEthical approval
Approval of trial protocol and informed consent docu-
ments have been obtained primarily from the University
of Munich Institutional Review Board (project number
275-14), followed by the responsible ethics committees
and/or state chambers of physicians of the 12 other
study centers (University of Munich Institutional Review
Board, ethics committee of the Medical Chamber of
Westphalia-Lippe, University of Regensburg Institutional
Review Board, ethics committee of the Medical Chamber
of Hamburg, ethics committee of the Hannover Medical
School, State Medical Chamber of Lower Saxony, institu-
tional review board of Berlin, ethics committee of the
Medical Chamber of Schleswig-Holstein, ethics committee
of the Heinrich-Heine University of Düsseldorf, institu-
tional review board of Greifswald, University of Aachen
Institutional Review Board and institutional review board
of the University of Ulm).
All study staff commit themselves to the Declaration of
Helsinki (2013 version), as well as to all pertinent national
laws and the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH) harmonized tripartite guide-
lines for Good Clinical Practice issued in June 1996
(http://www.ich.org/fileadmin/Public_Web_Site/ICH_Prod
ucts/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf) and the
European Medicines Agency’s CPMP/ICH/135/95 guide-
line (July 2002; http://www.edctp.org/fileadmin/documents/
EMEA_ICH-GCP_Guidelines_July_2002.pdf ). Important
protocol modifications will be reported to all relevant par-
ties. All participants complete informed consent forms prior
to participation in the trial.Inclusion and exclusion criteria
Inclusion criteria
Patients with an internal or external diagnosis of histo-
logically confirmed CIN 3, a colposcopically visible le-
sion and a positive high-risk HPV test (according to the
criteria of Meijer et al. [21]) who have had no previous
cervical surgery, no previous treatment of the disease,
are at least 18 years of age and provide written informed
consent are eligible for inclusion in the study.
Exclusion criteria
Patients are excluded at any time upon their request or if
any of the following applies: pregnancy at time of inclu-
sion and during the first 6 postoperative months, intake of
immunosuppressants, known HIV infection, malignant
disease requiring treatment or inadequate colposcopy.
Study blinding
To exclude bias by unconsciously different behavior, the
study is patient-blinded for the first 6 postoperative
months. In case of complications, however, access to the
surgical report is possible at any time.
Surgery
Both surgical techniques are performed using a thin,
low-voltage, electrified wire loop known as a loop elec-
trosurgical excision procedure electrode. Procedures are
performed by experienced surgeons at 13 German dys-
plasia centers under colposcopic control and are carried
out as shown in Figs. 1, 2, 3 and 4. A dysplastic cervical
lesion is identified after application of acetic acid and
iodine solution.
In the lesion-only resection, the dysplastic area is re-
moved with a safety margin of 2 mm. In the classical
LLETZ, the lesion, including the transformation zone, is
resected. Because the outer border of the transformation
zone cannot be determined colposcopically, the follow-
ing definition for resection of the transformation zone
Fig. 2 Resection margins in lesion-only operation, where a distance of 2 mm around the lesion should be kept. CIN, Cervical intraepithelial neoplasia
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the squamocolumnar junction, an area of 4 mm sur-
rounding the junction is defined as the transformation
zone. In the event that the iodine-negative zone is
greater than the defined area, the iodine-negative area is
considered the transformation zone and should be re-
moved as well.
Postoperatively, cone size is measured before fixation
by submergence in a fluid-filled cylindrical vial using
Archimedes’ principle. Afterward the specimen is evalu-
ated histologically for the grade of dysplasia and achieve-
ment of resection margins.
Postoperative controls
According to German guidelines, the first follow-up
examination is performed after an interval of 6 months.
A Pap smear, HPV test and colposcopy are performed.
In cases of colposcopically suspect lesions, a biopsy is
taken. A second postoperative control is carried out 12
months after conization.
Primary outcome measure
The primary endpoint is the rate of negative high-risk
HPV tests after 6 months, because a negative HPV test is
generally regarded as evidence of successful treatment.
The negative predictive value for a negative HPV test after
conization is between 92 % [16] and 100 % [22–26], and
successful treatment usually leads to the elimination of
the virus [27–30]. A negative HPV test therefore excludes
CIN persistence or recurrence with high probability. In
contrast, repeated positive HPV tests can be taken asFig. 3 Comparison of the extent of both surgical methods, example 1. LLETZ, Lasuspicious of a continuation of dysplasia or as an indicator
of recurrent dysplasia.Secondary outcome measure
Because it is possible, from a clinical point of view, that
patients who have received the lesion-only operation
simply need more time for the viral infection to be elim-
inated, HPV is tested again in the postoperative control
after 12 months. Further secondary endpoints are Pap
smear results in both postoperative controls, biopsy re-
sults (if applicable) and resection margins.Safety concerns
It should be noted that, even with classical conization,
resection margins are positive or only questionably nega-
tive in up to 25 % of cases.
If there is CIN 1 detectable at the cutting margins, re-
currence or persistence is expected in only 0 % to 5 % of
participants. In the case of CIN 3 at the surgical margins,
recurrence can be expected in 20 % to 25 %. If non in sano
resection happens at the endocervical margin, risk in-
creases to 30 %. If both, endo- and ectocervical resection
margins are affected with CIN 3, risk is highest with 50 %
[31]. Importantly, in those cases where immediate reconi-
zation is indicated because of positive surgical margins, no
dysplasia was detected in over 80 % of cases.
For this reason, an immediate reconization usually is
not indicated, but should be assessed according to indi-
vidual risk and discussed with the patient. Only after fur-
ther histological confirmation of CIN during the firstrge loop excision of the transformation zone; SCJ, Squamocolumnar junction
Fig. 4 Comparison of the extent of both surgical methods, example 2. LLETZ, Large loop excision of the transformation zone; SCJ, Squamocolumnar junction
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be recommended.
Thus, the initially conservative approach in terms of a
checkup after 6 months is also justified in the case of an
increased incidence of positive surgical margins. This
can be seen especially in light of the expected reduction
of complications associated with surgery.
Interim analysis and stopping rules
An interim analysis will be performed at the postoperative
6-month control of the first 250 patients included. The
primary outcome is the result of HPV tests. If the rate of
positive HPV tests after 6 months in patients who have
undergone lesion-only surgery is higher by more than
15 % than among patients who have had classical LLETZ,
the study will be terminated. Because the interim analysis
was included exclusively for safety reasons and thus does
not involve a test of the non-inferiority study hypothesis,
the probability of a type I error (that is, a false-positive
study result) should not be affected.
Additional investigations
Because HPV infection is the cause of dysplasia, further
analyses to investigate HPV infection are performed in a
subset of 250 patients. A particular focus is on the geno-
typing of HPV infection because often multiple infections
with different HPV types are present simultaneously, espe-
cially in young patients. Thus, there is the risk that, des-
pite eradication of the lesion-causing HPV type, the
conventional HPV test result may continue to be positive
because infection with another HPV type is present with-
out clinical consequence.
To make a statement with respect to a more valid clin-
ical consequence of HPV infection, detection of tran-
scriptional activity of E6 and E7 is analyzed. Expression
of viral oncoproteins E6 and E7 plays a crucial role in
HPV-mediated carcinogenesis, as it interferes with the
cell cycle, causes cell cycle progression (E7) and at thesame time prevents apoptosis (E6). This occurs through
the inactivation of oncosuppressor proteins p53 and ret-
inoblastoma protein (pRb). pRb in particular prevents
cells from entering S-phase and thus has antiprolifera-
tive effects [32–37]. As opposed to the mere detection of
HPV DNA, testing for the transcriptional activity of E6
and E7 can allow us to make a statement about the bio-
logical activity of the infection.
The described additional analyses are performed at five
study centers (Munich, Hannover, Wolfsburg, Berlin and
Regensburg).
Discussion
With knowledge about the obstetric complications of
cervical conization, surgical radicalism has increasingly
declined in recent years. To date, it has not yet been sys-
tematically analyzed whether consistent oncological
safety can be guaranteed by removing less tissue. In dis-
cussions about the optimal extent of conization with
leading colposcopists in Germany, it furthermore turns
out that the size of the cone varies significantly, depend-
ing on the individual surgeon.
The aim of this study is thus to define a universal
standard for cervical conization that combines the high-
est level of oncological safety with minimal obstetric
risk. To that end, we compare two surgical methods
with each other: (1) classical LLETZ, in which the lesion
is removed, including the transformation zone; and (2)
excision of the lesion only.
There are certain limitations to our study. In patients
in whom the entire transformation zone is affected by
the lesion but who will be randomized into the lesion-
only group, the extent of the operation would in fact be
the same as in patients randomized to undergo the clas-
sical LLETZ operation. This could ultimately lead to lim-
ited discrimination between the two study groups. To
evaluate this influence on the results, every surgeon must
indicate the extent of the dysplastic area (CIN/ectocervix
Schwarz et al. Trials  (2015) 16:225 Page 6 of 7in percent) at the time of the operation. However, includ-
ing only patients with small lesions would lead to a severe
selection bias by recruiting patients according to more
subjective criteria. Furthermore, generalization of the
study results could no longer be guaranteed, because only
a subgroup of patients with high-grade dysplastic lesions
would be included.
Trial status
As of May 2015, we are still recruiting participants.
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